<DOC>
	<DOCNO>NCT01706536</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel arm study . The study population consist subject , 35 75 year age , diagnosis moderate severe COPD per Global Initiative Chronic Obstructive Lung Disease guideline .</brief_summary>
	<brief_title>A Study Efficacy Safety EP-101 ( ( SUN101 ) Subjects With Moderate Severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel arm study . The study population consist subject , 35 75 year age , diagnosis moderate severe COPD per Global Initiative Chronic Obstructive Lung Disease guideline ( GOLD , 2011 ) . The primary analysis compare EP-101 ( SUN101 ) dose group placebo respect change baseline morning trough FEV1 Day 29 . Trough FEV1 define mean two FEV1 value obtain 23 hour 30 minute 24 hour Day 28 AM dose ( ie , approximately 12 hour previous PM dose ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Male female subject age 35 75 year , inclusive . A clinical diagnosis moderate severe COPD accord GOLD guideline ( 2011 ) . Current smoker exsmokers least 10 packyear smoke history ( eg , least 1 pack/day 10 year , equivalent ) . Postbronchodilator ( follow inhalation ipratropium bromide MDI ) FEV1 ≥ 30 % ≤ 70 % predict normal value Screening Period . Postbronchodilator ( follow inhalation ipratropium bromide MDI ) FEV1/FVC ratio &lt; 0.70 Screening Period . Postbronchodilator ( follow inhalation ipratropium bromide MDI ) improvement FEV1 ≥ 12 % ≥ 100 mL Screening Period . Ability perform reproducible spirometry accord American Thoracic Society ( ATS ) European Respiratory Society ( ERS ) guideline ( 2005 ) . Subject , female ≤ 65 year age child bear potential , must negative serum pregnancy test screening . Females childbearing potential must instruct agree avoid pregnancy study must use acceptable method birth control : . An oral contraceptive , intrauterine device ( IUD ) , implantable contraceptive , transdermal injectable contraceptive least 1 month prior enter study continue use throughout study thirty day follow study participation . b . Barrier method contraception , eg , condom and/or diaphragm spermicide participate study . c. Abstinence . Willing able provide write informed consent . Current evidence recent history clinically significant unstable disease ( COPD ) abnormality opinion Investigator would put subject risk would compromise quality study data ; include limit cardiovascular disease , myocardial infarction , cardiac failure , uncontrolled hypertension , lifethreatening arrhythmia , uncontrolled diabetes , neurologic neuromuscular disease , liver disease , gastrointestinal disease electrolyte abnormality . Current evidence history clinically significant abnormal cardiac rhythm and/or conduction finding , include Holter monitoring result Screening Period . Concomitant pulmonary disease primary diagnosis asthma . History malignancy organ system , treat untreated within past 5 year , exception localize basal cell carcinoma skin Recent history COPD exacerbation require hospitalization need increase treatment COPD within 6 week prior Screening Period . Use daily oxygen therapy &gt; 10 hour per day . Use systemic steroid within 3 month prior Screening Period . Respiratory tract infection within 6 week prior Screening Period . History tuberculosis , bronchiectasis nonspecific pulmonary disease . History urinary retention bladder neck obstruction type symptom . History narrowangle glaucoma . Prolonged QTc interval ( &gt; 450msec male &gt; 470msec female ) Screening Period , history long QT syndrome . Recent history ( previous 12 month ) excessive use abuse narcotic/illegal drug . History hypersensitivity intolerance β2agonists anticholinergic . Participation another investigational drug study drug receive within 30 day prior Screening Period . Female subject pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>